A research article, entitled “Country
Contribution to Investigators of Pivotal Clinical Trials and their Primary
Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021”,
authored by Yoona Choi, Jung-Hyun Won, Heeju Kim, YeSol Hong, Yujin Kim, and
Howard Lee, has been published in Clinical
Pharmacology & Therapeutics (CPT) on February 5, 2025. Clinical Pharmacology & Therapeutics (CPT) is one of the most prestigious journals in the field of clinical pharmacology (impact factor of 6.3 in 2023), reflecting its significant influence in
translational medicine and regulatory science.
This study investigated the geographical
distribution of investigators and authors in pivotal clinical trials (PCTs) for
new drugs approved by the U.S. Food and Drug Administration (FDA) from 2012 to
2021 and its association with the racial and ethnic diversity of study
participants. While PCTs are often conducted across
multiple countries to ensure broad participant enrollment and generalizability
of clinical trial findings, the diversity of trial participants remains
inadequate, with a predominant representation of White. To address this, the
study analyzed 429 new drugs, 734 PCTs, and 718 primary publications (PPubs),
extracting data from FDA labels, review s, PPubs, and
clinicaltrials.gov. The findings revealed that North America and Western Europe
(NAWE) accounted for the largest proportion of PCT investigators (62.9%), PPub
authors (81.7%), and lead authors (90.9%). Among 521 PPubs reporting racial and
ethnic distribution of participants, the median Diversity Index (DI) was 0.33,
with only 16.3% of PPubs exceeding a DI of 0.5.
This study shows that evidence generation
for new drug approval has remained concentrated in NAWE, with an even stronger
presence in PPub authorship. This study emphasizes that to improve the
racial/ethnic diversity of PCT participants, investigators from non-NAWE
countries should be encouraged to take on more leadership roles, thereby
increasing their likelihood of serving as authors in PPub.